ABI-007 in Treating Patients With Inoperable Locally Recurrent or Metastatic Melanoma

Phase 2 Completed Jonsson Comprehensive Cancer Center National Cancer Institute (NCI) · collab

Open-labelTreatment

Summary

RATIONALE: Drugs used in chemotherapy, such as ABI-007, work in different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: This phase II trial is studying how well ABI-007 works in treating patients with inoperable (unresectable) locally recurrent or metastatic melanoma.

Timeline

Start: 2004-02
Primary completion: —
Completion: 2010-01

Publications

Results Hersh EM, O'Day SJ, Ribas A, Samlowski WE, Gordon MS, Shechter DE, Clawson AA, Gonzalez R. A phase 2 clinical trial of nab-paclitaxel in previously treated and chemotherapy-naive patients with metastatic melanoma. Cancer. 2010 Jan 1;116(1):155-63. doi: 10.1002/cncr.24720.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Paclitaxel	Small molecule	100 mg/m2	Intravenous
Subject	Paclitaxel	Small molecule	150 mg/m2	Intravenous

ABI-007 in Treating Patients With Inoperable Locally Recurrent or Metastatic Melanoma

Summary

Timeline

Publications

Drugs

Indications